Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
|Articles|March 1, 2000
Supplements and Featured Publications
- Creating an Optimal Strategy for Managing Hypertension
- Volume 6
- Issue 4 Suppl
Critical Overview of Antihypertensive Therapies: What is Preventing Us from Getting There?
Author(s)Mark A. Munger, PharmD
Advertisement
Articles in this issue
over 26 years ago
Participating Facultyover 26 years ago
Introductionover 26 years ago
The Impact of the New HEDIS Guidelines: Practical Considerationsover 26 years ago
Impact and Risks of Untreated Hypertension on Managed Careover 26 years ago
Closing Remarksover 26 years ago
CE Quizover 26 years ago
Selected Abstractsover 26 years ago
BibliographyAdvertisement
Related to this article
Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.
Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
3
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
4
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
5